New chemoimmunotherapy study for lung cancer

May 28, 2019

In the last year, the combination of pembrolizumab (Keytruda) with chemotherapy has become a frontline treatment for people with metastatic non-small cell lung cancer (NSCLC). The FDA granted full approval for the combination treatment last August based on studies that showed a clear survival benefit over chemotherapy alone. 

A new phase 3 study of the combination treatment has opened at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. The new study focuses specifically on patients with TKI-resistant EGFR-mutated tumors. Patients without the mutations were found to have significantly longer overall survival and progression-free survival on the combination treatment (NEJM, May 31, 2018). The new study hopes to find similar benefits for those with the mutations. 

Get study details here:

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

Learn more about the studies leading to this at OncLive: Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC.

For more information or to enroll a patient in this study, please call our Clinical Research office at 503-215-2614.

See more studies

This study is one of 19 lung cancer studies currently open at Providence Cancer Institute. New research studies are added frequently. Please visit our website to see all open lung cancer studies

See all studies in all cancer types at Providence Cancer Institute. 

Multidisciplinary lung cancer management

The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking. 

Rachel Sanborn, M.D., co-director of the program, is the lead investigator of this featured study. Her research focuses on studying new agents or combinations of treatments for lung cancer, mesothelioma and other thoracic tumors.